Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congressGlobeNewsWire • 10/04/21
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's DiseaseBenzinga • 10/04/21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn's DiseaseGlobeNewsWire • 10/04/21
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISGlobeNewsWire • 09/17/21
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/07/21
Galapagos reports H1 financial results with refocused pipeline and operational progressGlobeNewsWire • 08/05/21
Galapagos' Another Psoriasis Candidate Shows Efficacy, Safety Profile In Mid-Stage StudyBenzinga • 07/15/21
Galapagos Shares Drop As SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis PatientsBenzinga • 07/15/21
Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammationGlobeNewsWire • 07/14/21
Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis studyGlobeNewsWire • 07/14/21
Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative ColitisGlobeNewsWire • 07/10/21
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congressGlobeNewsWire • 05/27/21
Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world settingGlobeNewsWire • 05/18/21
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/08/21
Galapagos Drops Early Metabolic & Osteoarthritis Programs, Reorganizes R&D EffortsBenzinga • 05/07/21
Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapiesGlobeNewsWire • 04/23/21